Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma.

ABSTRACT:

Background

TAS0313 is a multi-epitope long peptide vaccine targeting several cancer-associated antigens highly expressed in multiple cancer types, including glioblastoma (GBM). This cohort of a Phase 2 part evaluated the efficacy and safety of TAS0313 in patients with GBM.

Methods

TAS0313 (27 mg) was administered subcutaneously on Days 1, 8 and 15 of Cycles 1 and 2, and Day 1 of subsequent cycles in 21-day cycles. The primary endpoint was the objective response rate (ORR). The secondary endpoints were the disease control rate, progression-free survival (PFS) and 6- and 12-month progression-free survival rates (PFR) and safety. Immunological response was assessed as an exploratory endpoint.

Results

The best overall response was partial response in 1 patient, and the OR

SUBMITTER: Narita Y 

PROVIDER: S-EPMC9519730 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature